Novo Nordisk Intends to Appeal Adverse Ruling in Prandin (repaglinide) Patent Case

Novo Nordisk announced it would appeal the US District Court for the Eastern District of Michigan’s ruling regarding Novo Nordisk’s US patent covering combination drugs Prandin and PrandiMet. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.

Novo Nordisk markets repaglinide under the trade name Prandin and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin or PrandiMet will be available in the US market.

ASweetLife Team

The Novo Nordisk Pipeline: An Interview with CMO Todd Hobbs
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; as an endocrinologist (for ten years he ran a clinical…
Novo Nordisk Drops Oral Insulin Development Projects
According to an article published on Seeking Alpha, Novo Nordisk has decided to make some significant changes in its drug development strategy as a result of the 'current payment atmosphere’ in…

Be the First to Comment!